Talking about Morgan Stanley’s bullish call on Eli Lilly and Company (NYSE:LLY), Kevin Simpson, Capital Wealth Planning founder and CIO, said that he agrees with the call and thinks the company’s ...

MapLight Therapeutics has raised a $372.5 million series D round, clearing the biotech to chart a course through phase 2 for ...

Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts. On July 11, ...

Eli Lilly & Company (NYSE:LLY) ranks among the best non-tech stocks to buy according to billionaires. Eli Lilly & Company ...

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products for Human Use (CHMP) has ...

Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

Eli Lilly has cleared a major hurdle in its bid to win European approval for its Alzheimer's disease drug Kisunla.

Gate Bioscience Inc. has entered a collaboration and license agreement with Eli Lilly and Co. to discover, develop and ...